Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications

PHARMACEUTICALS(2023)

引用 0|浏览3
暂无评分
摘要
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: 133La, 132La, 134Ce/134La, and 226Ac for 225Ac TAT; 203Pb for 212Pb TAT; 131Ba for 223Ra and 224Ra TAT; 123I, 124I, 131I and 209At for 211At TAT; 134Ce/134La for 227Th TAT; and 155Tb and 152Tb for 149Tb TAT.
更多
查看译文
关键词
targeted alpha therapy,alpha particle therapy,PET imaging,SPECT imaging,targeted radionuclide therapy,theranostics,actinium-225,lanthanum-133,lead-212,lead-203
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要